Masofaniten
Based on 1 Customer Validation
Masofaniten (Androgen receptor-IN-2) is a potent and orally active androgen receptor inhibitor. Masofaniten has antitumor activity against prostate cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.72%
- CAS No.: 2416716-62-4
- Formule: C24H24Cl2N4O4S
- Masse moléculaire:535.44
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-138641
BavdegalutamideAR PROTAC Degrader -
HY-70002
EnzalutamideAndrogen Receptor Antagonist -
HY-15194
DimethylcurcuminAndrogen Receptor Inhibitor -
HY-100573
NecrosulfonamideMLKL/GSDMD Inhibitor -
HY-15531
VenetoclaxBCL-2 Inhibitor -
HY-19312
3-MethyladenineAutophagy/PI3K Inhibitor -
HY-15559
Hoechst 33342DNA Fluorescent Stain -
HY-10619
NiraparibPARP Inhibitor -
HY-Y0873
PEG300Neutral Polymer -
HY-114530
LY2452473Androgen Receptor Modulator -
HY-13027
DAPTγ-secretase Inhibitor -
HY-141520
ART558Polθ Inhibitor
Activité biologique
Description
IC50 & Target
Androgen receptor[1]
In Vitro
Masofaniten (compound A109, androgen-induced PSA-Luciferase assay) inhibits androgen binding to androgen receptor with an IC50 of 535 nM[1].
Masofaniten inhibits cell proliferation in LNCaP and LNCaP95 cells (IC50: 0.44 μM, 3.78 μM respectively)[1].
Masofaniten shows a metabolic stability in liver microsome with a t1/2 of more than 120 min, and in hepatocytes with a t1/2 of more than 360 min[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Masofaniten (5 mg/kg, p.o., single dose, in male CD-1 mice) shows a t1/2 of 8.1 h, Cmax of 2673.3 ng/mL, F (%) of 33.6[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LNCaP Xenografts Model[1]
-
Dosage:60 mg/kg
-
Administration:Oral administration (p.o.)
-
Result:Inhibited tumor growth no obvious drug related toxicity (bodyweight change).
Chemical Information
-
CAS No. 2416716-62-4
-
Appearance Solid
-
Masse moléculaire 535.44
-
Formule C24H24Cl2N4O4S
-
Color Off-white to light yellow
-
SMILES
CS(=O)(NC1=NC=CC(COC2=CC=C(C(C)(C3=CC(C#N)=C(OCCCl)C(Cl)=C3)C)C=C2)=N1)=O
-
Synonyms
Androgen receptor-IN-2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
In Vitro:
DMSO : 40 mg/mL (74.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8676 mL | 9.3381 mL | 18.6762 mL | 46.6906 mL |
| 5 mM | 0.3735 mL | 1.8676 mL | 3.7352 mL | 9.3381 mL | |
| 10 mM | 0.1868 mL | 0.9338 mL | 1.8676 mL | 4.6691 mL | |
| 15 mM | 0.1245 mL | 0.6225 mL | 1.2451 mL | 3.1127 mL | |
| 20 mM | 0.0934 mL | 0.4669 mL | 0.9338 mL | 2.3345 mL | |
| 25 mM | 0.0747 mL | 0.3735 mL | 0.7470 mL | 1.8676 mL | |
| 30 mM | 0.0623 mL | 0.3113 mL | 0.6225 mL | 1.5564 mL | |
| 40 mM | 0.0467 mL | 0.2335 mL | 0.4669 mL | 1.1673 mL | |
| 50 mM | 0.0374 mL | 0.1868 mL | 0.3735 mL | 0.9338 mL | |
| 60 mM | 0.0311 mL | 0.1556 mL | 0.3113 mL | 0.7782 mL |
Masofaniten Related Classifications
HY-136582 Related Classifications
Powered by Bioz